At the 2nd Congress of the European Academy of Neurology (EAN), held in Copenhagen, Denmark, from May 28–31 2016, Philip Scheltens, MD, PhD, from VU University Medical Center, Amsterdam, the Netherlands, discusses the clinical development of prevention strategies, including for reducing the development amyloid plaques in preclinical stages, for patients with Alzheimer’s disease.
